Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024
- Written by PR Newswire
![]() |
BOSTON, Aug. 5, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced that the orally administered CD73 small molecule inhibitor ATN-037 (also known as ATG-037) has been accepted for Mini Oral presentation atthe 2024 European Society of Medical Oncology Congress (EMSO Congress 2024), taking place from...















